NINTEDANIB and COUGH

Overview

COUGH is the #4 most commonly reported adverse reaction for NINTEDANIB, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 2,978 FDA adverse event reports linking NINTEDANIB to COUGH. This represents approximately 3.5% of all 85,660 adverse event reports for this drug.

NINTEDANIB has an overall safety score of 85 out of 100. Patients taking NINTEDANIB who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COUGH is moderately reported among NINTEDANIB users, representing a notable but not dominant share of adverse events.

Other Side Effects of NINTEDANIB

In addition to cough, the following adverse reactions have been reported for NINTEDANIB:

• DIARRHOEA — 9,428 reports
• NAUSEA — 4,456 reports
• DYSPNOEA — 3,762 reports
• DECREASED APPETITE — 2,922 reports
• DEATH — 2,883 reports
• WEIGHT DECREASED — 2,824 reports
• FATIGUE — 2,777 reports
• VOMITING — 2,617 reports
• IDIOPATHIC PULMONARY FIBROSIS — 1,938 reports
• CONSTIPATION — 1,932 reports

Other Drugs Associated with COUGH

The following drugs have also been linked to cough in FDA adverse event reports:

Does NINTEDANIB cause COUGH?

COUGH has been reported as an adverse event in 2,978 FDA reports for NINTEDANIB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COUGH with NINTEDANIB?

COUGH accounts for approximately 3.5% of all adverse event reports for NINTEDANIB, making it a notable side effect.

What should I do if I experience COUGH while taking NINTEDANIB?

If you experience cough while taking NINTEDANIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages